Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,997 shares of the pharmaceutical company’s stock after buying an additional 87 shares during the quarter. GAMMA Investing LLC’s holdings in Vertex Pharmaceuticals were worth $1,610,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc grew its position in shares of Vertex Pharmaceuticals by 105.0% in the 4th quarter. Versant Capital Management Inc now owns 330 shares of the pharmaceutical company’s stock valued at $133,000 after purchasing an additional 169 shares during the period. SK Wealth Management LLC acquired a new position in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $678,000. Principal Financial Group Inc. increased its position in shares of Vertex Pharmaceuticals by 5.6% during the third quarter. Principal Financial Group Inc. now owns 410,359 shares of the pharmaceutical company’s stock worth $190,850,000 after acquiring an additional 21,649 shares in the last quarter. Lord Abbett & CO. LLC raised its holdings in shares of Vertex Pharmaceuticals by 10.1% during the third quarter. Lord Abbett & CO. LLC now owns 3,279 shares of the pharmaceutical company’s stock worth $1,525,000 after acquiring an additional 300 shares during the period. Finally, Oddo BHF Asset Management Sas bought a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at $7,912,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Ratings Changes

VRTX has been the topic of a number of recent research reports. Barclays dropped their target price on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research report on Friday, December 20th. Royal Bank of Canada lifted their price target on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, December 20th. Raymond James reiterated a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Finally, Canaccord Genuity Group raised their target price on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research note on Wednesday, November 6th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $494.04.

Vertex Pharmaceuticals Stock Up 0.3 %

VRTX stock opened at $407.11 on Friday. The stock has a market capitalization of $104.84 billion, a P/E ratio of -204.58 and a beta of 0.36. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $456.78 and a 200-day moving average price of $470.61. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.67 EPS. As a group, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.